Shares of Tyme Technologies, Inc. (NASDAQ:TYME) have been given an average broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.
Brokerages have set a twelve-month consensus price target of $8.33 for the company and are predicting that the company will post ($0.06) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Tyme Technologies an industry rank of 169 out of 265 based on the ratings given to related companies.
Several research analysts recently issued reports on the stock. Canaccord Genuity assumed coverage on shares of Tyme Technologies in a report on Wednesday, January 3rd. They set a “buy” rating for the company. Evercore ISI assumed coverage on shares of Tyme Technologies in a report on Friday, November 17th. They set an “outperform” rating and a $7.00 price target for the company. BidaskClub raised shares of Tyme Technologies from a “sell” rating to a “hold” rating in a report on Thursday, January 4th. Finally, HC Wainwright assumed coverage on shares of Tyme Technologies in a report on Friday, December 15th. They set a “buy” rating and a $8.00 price target for the company.
Tyme Technologies (NASDAQ:TYME) opened at $6.74 on Wednesday. The stock has a market cap of $618.99, a PE ratio of -39.65 and a beta of -0.01. Tyme Technologies has a 1-year low of $2.01 and a 1-year high of $9.50.
COPYRIGHT VIOLATION WARNING: “” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/1800553-2/1800553.html.
About Tyme Technologies
Tyme Technologies, Inc is a clinical-stage biotechnology company. The Company is focused on developing cancer therapeutics that is intended to be broadly effective across tumor types and have low toxicity profiles. The Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.